Publications by authors named "D Vareslija"
The breast epithelium, vital for mammary gland function, is influenced by oestrogen through the oestrogen receptor (ER) signalling pathway. Luminal breast cancer (BC), characterised by ER expression, comprises the majority of all BCs and presents significant clinical challenges due to therapy resistance and recurrence. Despite advancements in understanding luminal disease, improving long-term survival and reducing relapse of BC patients by predicting therapy efficacy and understanding resistance mechanisms remain critical challenges.
View Article and Find Full Text PDFArticle Synopsis
- RET is highlighted as a crucial player in breast cancer brain metastases, with overexpression linked to enhanced cancer cell adhesion and survival in the brain.
- The study utilizes various methods, including pharmacological inhibition and RNA sequencing, to explore RET's functionality and mechanisms in patient-derived tumor samples.
- Findings suggest that targeting RET could be a promising management strategy for breast cancer patients with brain metastases, particularly in those with estrogen receptor-positive tumors.
Purpose Of Review: Homologous recombination repair deficiency (HRD) increases breast cancer susceptibility and influences both prophylactic and active management of breast cancer. This review evaluates HRD testing and the therapeutic implications of HRD in a global context.
Recent Findings: Ongoing research efforts have highlighted the importance of HRD beyond BRCA1/2 as a potential therapeutic target in breast cancer.
Purpose Of Review: In the last decade, poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in the treatment of several cancers, such as breast and ovarian cancer. This article aims to discuss the current uses, limitations, and future directions for PARP inhibitors (PARPis) in the treatment of breast cancer.
Recent Findings: Following the results of the OlympiAD and EMBRACA trials, PARPis were approved in HER2-negative breast cancer with a germline BRCA mutation.